Daymark Wealth Partners LLC Grows Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Daymark Wealth Partners LLC boosted its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 65.2% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 76,000 shares of the biopharmaceutical company’s stock after buying an additional 30,000 shares during the period. Daymark Wealth Partners LLC’s holdings in Revance Therapeutics were worth $195,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of RVNC. Arizona State Retirement System boosted its stake in shares of Revance Therapeutics by 27.6% in the second quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,996 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Revance Therapeutics by 67.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 6,826 shares during the period. Sei Investments Co. boosted its stake in Revance Therapeutics by 52.5% in the 2nd quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 7,628 shares during the period. California State Teachers Retirement System grew its holdings in Revance Therapeutics by 9.8% during the 1st quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 8,668 shares in the last quarter. Finally, Certuity LLC bought a new stake in shares of Revance Therapeutics during the second quarter valued at approximately $26,000. 97.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RVNC. William Blair reaffirmed a “market perform” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Piper Sandler cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Stifel Nicolaus dropped their price target on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Ten research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $10.50.

Revance Therapeutics Price Performance

Shares of RVNC stock opened at $5.36 on Friday. The company has a market cap of $561.84 million, a PE ratio of -1.48 and a beta of 1.00. Revance Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $12.07. The stock’s 50 day simple moving average is $5.49 and its two-hundred day simple moving average is $4.27.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.12. The company had revenue of $65.39 million for the quarter, compared to analysts’ expectations of $66.30 million. The business’s quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.80) EPS.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.